Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05881512 · ClinicalTrials.gov registry record · NA

Early Feasibility Study of Transcutaneous Upper Airway Stimulation in Obstructive Sleep Apnea

A NA study of Obstructive Sleep Apnea and OSA, sponsored by Somnial.

Completed
Registry status
NA
Development phase
12
Enrollment target
1
Study location

NCT05881512 is a NA study of Obstructive Sleep Apnea and OSA that has completed, run by Somnial. The registered enrollment target is 12 participants, below the 222-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05881512, a NA study of Obstructive Sleep Apnea and OSA, has completed, sponsored by Somnial.

COMPLETED
Registry status
NA
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

Early feasibility study to estimate the functionality of a novel intervention based on non-invasive transcutaneous electrical stimulation of the hypoglossal nerve to reduce the Apnea Hypopnea Index (AHI).

Interventions

  • DEVICE Transcutaneous Upper Airway Stimulation Device

Study Locations (1)

New York

  • United Diagnostics - Commack

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2022-09-12
Est. Completion 2023-02-22
Phase NA

Sponsor

Somnial

1 total trials

What the Registry Record Tells You About NCT05881512

The ClinicalTrials.gov registry entry for NCT05881512 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 222-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (95% lower). The listed sponsor is Somnial, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Obstructive Sleep Apnea appearing as the primary indexed condition, and to 1 intervention - of which Transcutaneous Upper Airway Stimulation Device is the first listed.

NCT05881512 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05881512 about?

NCT05881512 is a clinical study titled "Early Feasibility Study of Transcutaneous Upper Airway Stimulation in Obstructive Sleep Apnea". Early feasibility study to estimate the functionality of a novel intervention based on non-invasive transcutaneous electrical stimulation of the hypoglossal nerve to reduce the Apnea Hypopnea Index (AHI).

What is the current status of trial NCT05881512?

This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2022-09-12. Estimated completion is 2023-02-22.

What conditions does trial NCT05881512 study?

This clinical trial studies the following conditions: Obstructive Sleep Apnea, OSA.

What interventions are being tested in trial NCT05881512?

The interventions under investigation include: Transcutaneous Upper Airway Stimulation Device (DEVICE).

Who is sponsoring clinical trial NCT05881512?

This trial is sponsored by Somnial, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05881512 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obstructive Sleep Apnea

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.